159 related articles for article (PubMed ID: 32459546)
1. Outcomes of juvenile myelomonocytic leukemia patients after sequential therapy with cytarabine and 6-mercaptopurine.
Wajid M A; Gupta AK; Das G; Sahoo D; Meena JP; Seth R
Pediatr Hematol Oncol; 2020 Oct; 37(7):573-581. PubMed ID: 32459546
[TBL] [Abstract][Full Text] [Related]
2. Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children's Oncology Group.
Stieglitz E; Ward AF; Gerbing RB; Alonzo TA; Arceci RJ; Liu YL; Emanuel PD; Widemann BC; Cheng JW; Jayaprakash N; Balis FM; Castleberry RP; Bunin NJ; Loh ML; Cooper TM
Pediatr Blood Cancer; 2015 Apr; 62(4):629-36. PubMed ID: 25704135
[TBL] [Abstract][Full Text] [Related]
3. Juvenile myelomonocytic leukemia with PTPN11 mutation in a 23-month-old girl.
Jakovljević G; Kardum-Skelin I; Rogosić S; Nakić M
Coll Antropol; 2010 Mar; 34(1):251-4. PubMed ID: 20432758
[TBL] [Abstract][Full Text] [Related]
4. Cytosine arabinoside and mitoxantrone followed by second allogeneic transplant for the treatment of children with refractory juvenile myelomonocytic leukemia.
Patel SA; Coulter DW; Grovas AC; Gordon BG; Harper JL; Warkentin PI; Wisecarver JL; Sanger WG; Coccia PF
J Pediatr Hematol Oncol; 2014 Aug; 36(6):491-4. PubMed ID: 24322499
[TBL] [Abstract][Full Text] [Related]
5. Management of Two Juvenile Myelomonocytic Leukemia Patients According to Clinical and Genetic Features.
Tüfekçi Ö; Ören H; Demir Yenigürbüz F; Gözmen S; Karapınar TH; İrken G
Turk J Haematol; 2015 Jun; 32(2):175-9. PubMed ID: 26316488
[TBL] [Abstract][Full Text] [Related]
6. Central nervous system lesions due to juvenile myelomonocytic leukemia progressed in a boy undergoing first line chemotherapy.
Fukushima H; Fukushima T; Hiraki A; Suzuki R; Mahmoud SS; Yoshimi A; Nakao T; Kato K; Kobayashi C; Koike K; Fukasawa M; Morishita Y; Doisaki S; Muramatsu H; Sumazaki R
Int J Hematol; 2012 May; 95(5):581-4. PubMed ID: 22461033
[TBL] [Abstract][Full Text] [Related]
7. Molecular assessment of pretransplant chemotherapy in the treatment of juvenile myelomonocytic leukemia.
Hecht A; Meyer J; Chehab FF; White KL; Magruder K; Dvorak CC; Loh ML; Stieglitz E
Pediatr Blood Cancer; 2019 Nov; 66(11):e27948. PubMed ID: 31347788
[TBL] [Abstract][Full Text] [Related]
8. Non-hematopoietic stem cell transplantation treatment of juvenile myelomonocytic leukemia: a retrospective analysis and definition of response criteria.
Bergstraesser E; Hasle H; Rogge T; Fischer A; Zimmermann M; Noellke P; Niemeyer CM
Pediatr Blood Cancer; 2007 Oct; 49(5):629-33. PubMed ID: 16991133
[TBL] [Abstract][Full Text] [Related]
9. [Allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia].
Shao Q; Wang ZD; Zheng XL; Dong L; Han DM; Yan HM; Wang HX; Duan LN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1058-62. PubMed ID: 25130828
[TBL] [Abstract][Full Text] [Related]
10. Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial.
Niemeyer CM; Flotho C; Lipka DB; Starý J; Rössig C; Baruchel A; Klingebiel T; Micalizzi C; Michel G; Nysom K; Rives S; Schmugge Liner M; Zecca M; Schönung M; Baumann I; Nöllke P; Benettaib B; Biserna N; Poon J; Simcock M; Patturajan M; Menezes D; Gaudy A; van den Heuvel-Eibrink MM; Locatelli F
Blood Adv; 2021 Jul; 5(14):2901-2908. PubMed ID: 34297046
[TBL] [Abstract][Full Text] [Related]
11. Juvenile myelomonocytic leukemia: analyses of treatment results in the EORTC Children's Leukemia Cooperative Group (CLCG).
Lutz P; Zix-Kieffer I; Souillet G; Bertrand Y; Dhooge C; Rubie C; Mazingue F; Marguerite F; Machinaud-Lacroix F; Rialland X; Plouvier E; Behar C; Vilmer E; Philippe N; Otten J
Bone Marrow Transplant; 1996 Dec; 18(6):1111-6. PubMed ID: 8971380
[TBL] [Abstract][Full Text] [Related]
12. Transplantation for juvenile myelomonocytic leukemia: a retrospective study of 30 children treated with a regimen of busulfan, fludarabine, and melphalan.
Yabe M; Ohtsuka Y; Watanabe K; Inagaki J; Yoshida N; Sakashita K; Kakuda H; Yabe H; Kurosawa H; Kudo K; Manabe A;
Int J Hematol; 2015 Feb; 101(2):184-90. PubMed ID: 25504334
[TBL] [Abstract][Full Text] [Related]
13. Impact of Blood Count Recovery-based Complete Remission Before Allogeneic Hematopoietic Stem Cell Transplantation on Survival in Patients With Acute Myeloid Leukemia.
Ciftciler R; Demiroglu H; Buyukasık Y; Aksu S; Goker H
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):e205-e212. PubMed ID: 30665867
[TBL] [Abstract][Full Text] [Related]
14. Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcome.
Bouchacourt B; Hospital MA; Zemmour C; Rey J; d'Incan E; Charbonnier A; Mohty B; Saillard C; Bonnet S; Collignon A; Gelsi-Boyer V; Mozziconacci MJ; Blaise D; Vey N
Ann Hematol; 2020 Apr; 99(4):773-780. PubMed ID: 32088745
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and treatment of juvenile myelomonocytic leukemia in Slovak Republic: novel approaches.
Fabri O; Horakova J; Bodova I; Svec P; Laluhova Striezencova Z; Bubanska E; Cermak M; Galisova V; Skalicka K; Vaska A; Doczyova D; Panikova A; Sykora T; Adamcakova J; Kolenova A
Neoplasma; 2019 Sep; 66(5):818-824. PubMed ID: 31129971
[TBL] [Abstract][Full Text] [Related]
16. Development of T-cell acute lymphoblastic leukemia in a patient in very long lasting complete remission of juvenile myelomonocytic leukemia.
Maschan AA; Khachatrian LA; Solopova GG; Ossipova EY; Baidun LV; Dmitrieva SV; Maschan MA; Resnik IB
J Pediatr Hematol Oncol; 2011 Jan; 33(1):e32-4. PubMed ID: 21102353
[TBL] [Abstract][Full Text] [Related]
17. Sustained remission with azacitidine monotherapy and an aberrant precursor B-lymphoblast population in juvenile myelomonocytic leukemia.
Hashmi SK; Punia JN; Marcogliese AN; Gaikwad AS; Fisher KE; Roy A; Rao P; Lopez-Terrada DH; Ringrose J; Loh ML; Niemeyer CM; Rau RE
Pediatr Blood Cancer; 2019 Oct; 66(10):e27905. PubMed ID: 31250550
[TBL] [Abstract][Full Text] [Related]
18. Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine-based consolidation chemotherapy for adults with secondary acute myelogenous leukemia in first remission.
Schiller G; Lee M; Paquette R; Sawyers C; Khoubian F; Territo M
Leuk Lymphoma; 1999 May; 33(5-6):475-84. PubMed ID: 10342575
[TBL] [Abstract][Full Text] [Related]
19. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
[TBL] [Abstract][Full Text] [Related]
20. A retrospective analysis of azacitidine treatment for juvenile myelomonocytic leukemia.
Honda Y; Muramatsu H; Nanjo Y; Hirabayashi S; Meguro T; Yoshida N; Kakuda H; Ozono S; Wakamatsu M; Moritake H; Yasui M; Sano H; Manabe A; Sakashita K
Int J Hematol; 2022 Feb; 115(2):263-268. PubMed ID: 34714526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
